← Back to CB-13

CB-13 Stats & Data

Cra-13 Sab-378

PubChem CID 9799417

NPS DataHub

MW368.48

FormulaC26H24O2

CAS432047-72-8

IUPACnaphthalen-1-yl-(4-pentoxynaphthalen-1-yl)methanone

SMILESCCCCCOc1ccc(C(=O)c2cccc3ccccc23)c2ccccc12

InChIKeyRSUMDJRTAFBISX-UHFFFAOYSA-N

Chemical Class Naphthoylnaphthalene

Psychoactive Class Depressant / Psychedelic

Half-Life Rodent t½ reported around several hours; human half-life not established publicly. Space doses widely (≥8–12 h) to avoid accumulation.

Measured Affinities

Guide to PHARMACOLOGY

Measured binding and functional data for CB-13, curated by the IUPHAR/BPS Guide to PHARMACOLOGY. Each row cites the paper it came from. Lower concentrations mean tighter binding — a value in the sub-nanomolar range indicates a very potent interaction.

Target	Action	Measure	Value	Concentration	Species	Source
CB2 receptor CNR2	Agonist	pKi	7.72	19.05 nM	Human	PMID 22284817
CB1 receptor CNR1	Agonist	pKi	7.46	34.67 nM	Human	PMID 22284817

Reading this. pKi, pEC50 and pIC50 are negative log molar values, so a higher number means a tighter interaction; the concentration column converts them for you. Values from non-human species are laboratory measurements and do not translate directly to human effect. Receptor affinity is not a dose — it describes what a molecule binds, not how much of it is safe to take.

Receptor data from the IUPHAR/BPS Guide to PHARMACOLOGY (v2026.2), licensed CC BY-SA 4.0. Matched to this substance by InChIKey.

Effect Profile

Curated

Psychedelic 5.6

Moderate visuals with mild headspace and auditory effects, low body load

Visual Intensity×3

Headspace Depth×3

Auditory Effects×1

Body Load / Somatic Effects×1

Based on reports from:

Erowid Experience Reports PsychonautWiki CB-13

Tolerance & Pharmacokinetics

drugs.wiki

Half-Life

Rodent t½ reported around several hours; human half-life not established publicly. Space doses widely (≥8–12 h) to avoid accumulation.

Addiction Potential

Low–moderate psychological dependence risk, comparable to THC; physical dependence unlikely. Reinforcing properties appear weaker than centrally active cannabinoids due to poor brain penetration at typical doses.

Tolerance Decay

Full tolerance 5d Half tolerance 14d Baseline ~28d

Based on cannabinoid-class tolerance patterns: repeated daily activation downregulates CB1 signaling with partial reversal over days to weeks. Data specific to CB‑13 in humans are lacking; values above are heuristic. Evidence quality: anecdotal and cannabinoid-class extrapolation.

Cross-Tolerances

THC and other CB1 agonists

50% ●○○

Harm Reduction

drugs.wiki

• Identity warning: “CB‑13” refers to at least two unrelated cannabinoids in the literature. Recreational markets and some lists use “CB‑13” for a naphthoyl–naphthyl ketone, while pharmacology papers use CB‑13 = SAB‑378 (peripherally restricted CB1/CB2 agonist). Verify you have SAB‑378; misidentification increases risk.

• Peripherally restricted does not guarantee zero central effects: very high plasma levels or BBB changes (e.g., illness, co-intoxication) can allow some CNS penetration, so treat impairment as possible at higher doses. This is a general BBB principle for peripherally targeted drugs.

• Cannabinoids can cause tachycardia and lower blood pressure; standing up quickly may cause light-headedness or fainting. Sit/lie down if dizzy; avoid combining with other vasodilators (e.g., poppers, PDE5 inhibitors).

• Avoid driving or hazardous tasks until fully sober and well rested; cannabis-like agents are associated with increased motor vehicle crash risk, especially when combined with alcohol. A conservative minimum of 6–8 h is advisable after oral dosing.

• If acquired as an unlabeled powder, consider laboratory drug checking (GC/MS, LC/MS) to confirm identity/purity. Note some services do not accept cannabis/cannabinoid products, but may analyze powders.

• Smoking/vaping synthetic cannabinoids has historically led to uneven dosing and ‘hot pockets’ in herbal blends; if vaporizing neat material, use the lowest effective temperature and small test puffs to reduce pyrolysis exposure. Avoid homemade sprayed herbal products.

• Start with an allergy test (e.g., ≤25 mg oral or ≤5 mg vapor) due to unknown excipients and the absence of formal human safety data; increase in small steps with long waits (≥2–3 h oral; ≥45–60 min inhaled) before redosing. Rationale: unregulated supply variability and cannabinoid interindividual sensitivity.

• Combining with CNS depressants (alcohol, opioids, benzodiazepines, sedating antihistamines) markedly increases sedation and accident risk; with opioids and/or gabapentinoids the risk of respiratory depression is higher than either alone.

• Expected effects are mostly peripheral (analgesia, anti-inflammatory, body relaxation, mild warmth) with relatively muted classic cannabis ‘high’; users often report sedation and dry mouth, and at higher doses nausea or orthostatic symptoms.

• Legal and market shifts can lead to mislabeling with other potent synthetic or semi-synthetic cannabinoids; variable potency between batches is well-documented. Test a new batch cautiously.

References

Cited references

← Back to CB-13